CLINICAL TRIALS PROFILE FOR PRILOCAINE HYDROCHLORIDE

505(b)(2) Clinical Trials for Prilocaine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01073371 ↗	Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia	Completed	Conselho Nacional de Desenvolvimento Científico e Tecnológico	Phase 1	2008-07-01	This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers.
New Formulation	NCT01073371 ↗	Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 1	2008-07-01	This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers.
New Formulation	NCT01073371 ↗	Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia	Completed	University of Campinas, Brazil	Phase 1	2008-07-01	This blinded randomized, crossover, three period study aim to evaluate the anesthetic efficacy of liposome-encapsulated 3% prilocaine compared to 3% plain prilocaine and 3% prilocaine with 0,03IU/mL felypressin, after 1.8mL infiltration in the buccal sulcus of the maxillary right canine, in 32 volunteers.

All Clinical Trials for Prilocaine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00154167 ↗	Safety and Efficacy Study of NV-101 in Dental Patients	Completed	Novalar Pharmaceuticals, Inc.	Phase 2	2003-02-01	The purpose of this study was: - to determine if NV-101 accelerates recovery from numbness compared to placebo - to evaluate safety of NV-101
NCT00355277 ↗	Local Anaesthetic Effects of Transcutaneous Amitriptyline	Completed	University Hospital, Clermont-Ferrand	Phase 1	2005-11-01	The aim of this study is to assess the local anaesthetic effects of amitriptyline applied on the skin of human volunteers, considering the differential effects on mechanic and thermic sensitivity, the local and general tolerance, and the systemic absorption of the drug. The solution used for dilution of amitriptyline is the only one known to allow transcutaneous absorption of the drug [1]. Considering that the peripheral sensitive fibre is a possible site of action of tricyclic antidepressants for relieving neuropathic pain [2,3], this is a first step study before further assessment of the therapeutic effects of transcutaneous amitriptyline.
NCT00408941 ↗	EEG and Auditory Evoked Potentials During Local Anesthesia	Unknown status	Technische Universität München	Phase 4	2006-12-01	The aim of the present study was to investigate the sensitivity of AEP (auditory evoked potentials) to muscular artefacts using sedation and local anesthesia.
NCT00444626 ↗	A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)	Completed	Mentor Worldwide, LLC	Phase 3	2007-05-01	The purpose of this research study is to evaluate the safety and effectiveness of injection with DGE Injectable Gel (hyaluronic acid with lidocaine manufactured by Genzyme Biosurgery) as compared to injection with Restylane (a Food and Drug Administration (FDA) approved dermal filler) in patients undergoing cutaneous correction of the nasolabial folds (NLFs).
NCT00444626 ↗	A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)	Completed	Genzyme, a Sanofi Company	Phase 3	2007-05-01	The purpose of this research study is to evaluate the safety and effectiveness of injection with DGE Injectable Gel (hyaluronic acid with lidocaine manufactured by Genzyme Biosurgery) as compared to injection with Restylane (a Food and Drug Administration (FDA) approved dermal filler) in patients undergoing cutaneous correction of the nasolabial folds (NLFs).

Clinical Trial Conditions for Prilocaine Hydrochloride

Condition Name

Condition Name for Prilocaine Hydrochloride
Intervention	Trials
Pain	14
Healthy	6
Spinal Anesthesia	5
Pain, Acute	4

Condition MeSH

Condition MeSH for Prilocaine Hydrochloride
Intervention	Trials
Pain, Postoperative	7
Acute Pain	5
Premature Birth	4
Premature Ejaculation	4

Clinical Trial Locations for Prilocaine Hydrochloride

Trials by Country

Trials by Country for Prilocaine Hydrochloride
Location	Trials
United States	45
Egypt	22
Belgium	10
Turkey	8
France	7

Trials by US State

Trials by US State for Prilocaine Hydrochloride
Location	Trials
North Carolina	4
New York	4
California	4
Utah	3
Florida	3

Clinical Trial Progress for Prilocaine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Prilocaine Hydrochloride
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Prilocaine Hydrochloride
Clinical Trial Phase	Trials
Completed	72
Recruiting	15
Unknown status	14

Clinical Trial Sponsors for Prilocaine Hydrochloride

Sponsor Name

Sponsor Name for Prilocaine Hydrochloride
Sponsor	Trials
Cairo University	10
Assiut University	5
Plethora Solutions Ltd	5

Sponsor Type

Sponsor Type for Prilocaine Hydrochloride
Sponsor	Trials
Other	138
Industry	14
OTHER_GOV	2

Prilocaine Hydrochloride Market Analysis and Financial Projection

Last updated: April 28, 2026

Prilocaine Hydrochloride: Clinical Trial Update, Market Analysis, and Pricing-Proximate Projections

Prilocaine hydrochloride is a local anesthetic used in dentistry, dermatology, and procedural anesthesia settings, sold largely as generic products. Market visibility and trial attribution are constrained by low clinical-trial branding and frequent generic/combination formulations that do not map cleanly to a single “prilocaine HCl” development pipeline.

What does the current clinical trial landscape look like for prilocaine hydrochloride?

Clinical trials: how the evidence shows up

Prilocaine hydrochloride is widely used off-patent. In this profile, “clinical trial updates” typically appear as:

• New formulations (e.g., gels, sprays, combinations with other anesthetics).
• Comparative studies (prilocaine-containing regimens versus lidocaine or topical combinations).
• Safety-focused studies (dose limits, methemoglobinemia risk monitoring, pediatric or procedural endpoints).
• Device-adjacent trials (delivery systems that change pharmacokinetics and onset time).

Clinical development status (high-level)

No single, branded prilocaine hydrochloride late-stage program dominates global trial reporting. Instead, the research pattern is consistent with:

• Incremental, formulation-level studies
• Comparatives in routine procedural indications
• Safety monitoring in at-risk populations

Key clinical endpoints typically used

Across prilocaine-containing studies, the endpoints that determine regulatory and formulary acceptance tend to be:

• Onset time and duration of anesthesia
• Pain score reduction (visual analog scale or equivalent)
• Procedure success rate (need for rescue anesthetic)
• Adverse events frequency
• Methemoglobinemia indicators (measured or clinically monitored)

Where does prilocaine hydrochloride make revenue: indications and formulation demand?

Primary use settings

Prilocaine HCl demand concentrates in:

• Dental procedures (topical anesthesia and injection anesthetic use)
• Superficial dermatologic procedures (topical gels and creams)
• Procedural analgesia where topical or local infiltration is appropriate

Product format mix

Commercial availability is typically:

• Topical products: creams, gels, and viscous formulations for mucosal or skin anesthesia
• Injection formulations: local infiltration for dental and minor procedures
• Combination products: where prilocaine is paired with other local anesthetics (and sometimes adjuncts)

Why generic penetration matters for market sizing

The prilocaine hydrochloride market behaves like a mature generic segment:

• Pricing tracks local anesthetic benchmarks and competitor generics
• Differentiation shifts to formulation, vehicle, and regulatory positioning
• Brand-level “pipeline” narratives do not drive category growth the way they do for patented drugs

Market analysis: who buys, where volumes come from, and how pricing behaves?

Demand drivers

Demand expands with:

• High procedure volume in dentistry and dermatology
• Clinical preference for quick-onset topical anesthesia (where available)
• Competitive substitution among local anesthetics (lidocaine is the main comparator)

Competitive landscape

Prilocaine HCl competes primarily with:

• Other local anesthetics (especially lidocaine-based products)
• Generic equivalents within prilocaine formats
• Combination and device-delivered anesthetic systems

Pricing behavior

In a mature generic category, pricing typically depends on:

• Regulatory status (market exclusivity and listing)
• Pack size and concentration
• Manufacturing and sourcing costs
• Competition intensity at the national level

As a result, most revenue capture comes from:

• Distribution reach
• Tender and formulary inclusion
• Consistency of supply

How should investors and R&D leaders project future performance?

Projection logic for a mature generic

For prilocaine hydrochloride, projection should be framed as a category and formulation share exercise rather than a discovery pipeline exercise:

• Unit growth ties to procedure volumes and prescribing behavior
• Value growth ties to inflation-adjusted pricing and mix (topical versus injection, and higher-concentration products)
• Share changes tie to tender outcomes and distribution strength

Three scenario framework (directional)

Below is a projection framework that reflects how mature generics typically behave. It is intended to guide decision-making on go-to-market and portfolio planning.

Scenario A: Stable category

• Unit demand stays flat to low single-digit growth
• Pricing declines slow and stabilize
• Mix shifts modestly toward preferred vehicles (creams/gels with faster onset)

Result: revenue growth tracks procedure growth and minor mix effects.

Scenario B: Competitive pressure persists

• Additional generic entrants or aggressive tender pricing compress margins
• Pricing continues downward faster than unit growth

Result: revenue can still grow, but profitability compresses and working capital becomes more important.

Scenario C: Mix-driven uplift

• Uptake increases for topical formulations with improved onset and tolerability
• Select regions increase reimbursement or tender preference

Result: value grows faster than units due to mix and pricing stabilization in premium formulations.

Most actionable “projection levers”

For a company planning investment or partnerships around prilocaine HCl:

• Formulation improvements that shorten onset or improve handling (spreadability, adhesion, comfort)
• Regulatory strategy focused on market access and listing rather than novelty
• Supply reliability for tenders (avoid stockouts, stabilize lead times)
• Channel strategy for dentistry chains and dermatology procedural providers

Patent and regulatory context: what constrains development and value?

Prilocaine hydrochloride is an old, off-patent active ingredient in most major markets. The investable value usually comes from:

• New formulation patents (vehicle, delivery system, or method-of-use)
• Combination products (fixed-dose combinations)
• New indications or dosing regimens that are still protectable
• Manufacturing processes that can be protected

When patent coverage on the base active ingredient is absent, clinical programs and economic modeling must be tied to the protectable part of the product.

Clinical trial update template for decision-making (use this lens on any new studies)

When new trials appear for prilocaine-containing products, the decision signal depends on whether they change:

• Clinical differentiation (meaningful onset/duration superiority)
• Safety profile (reduced adverse events, lower methemoglobinemia risk under defined dosing)
• Operational value (shorter chair time in dentistry, lower need for rescue anesthetics)
• Regulatory positioning (new labeling that supports reimbursement or formulary inclusion)

Key Takeaways

• Prilocaine hydrochloride is a mature local anesthetic category with development centered on formulations and comparatives, not a dominant late-stage brand pipeline.
• Market value depends on generic competition, distribution reach, tenders, and mix shifts between topical and injection formats.
• Practical projections should use a scenario approach driven by procedure volume, pricing stabilization, and mix rather than patent-driven growth.
• Investment and R&D decisions should prioritize protectable formulation elements and evidence that changes clinical and operational outcomes.

---

FAQs

1) Is prilocaine hydrochloride currently driven by brand-new clinical development?

No. Clinical research tends to show up as formulation-level studies, comparatives, and safety monitoring rather than a single dominating late-stage branded program.

2) What are the main competitive benchmarks for prilocaine products?

Lidocaine-based topical and injectable local anesthetics are the most frequent comparators, along with other generic equivalents within the same delivery format.

3) What safety signal matters most in topline prilocaine trials?

Methemoglobinemia monitoring, dose limits, and adverse event rates under defined dosing regimens.

4) What changes market value the most for mature prilocaine products?

Mix (topical versus injection, and premium vehicles) and tender/formulary positioning rather than new mechanism innovation.

5) How should a company build an economic projection for prilocaine hydrochloride?

Model unit demand from procedure volumes, value from pricing and mix, and share from listing and tender outcomes under competitive pricing scenarios.

---

References

[1] FDA. Drug labeling information and safety communications for local anesthetics and methemoglobinemia risk (search platform). U.S. Food and Drug Administration.
[2] EMA. European public assessment reports and product information for local anesthetic formulations containing prilocaine (search platform). European Medicines Agency.
[3] ClinicalTrials.gov. Search results for “prilocaine” and “prilocaine hydrochloride” trials, including topical and dental procedural studies. U.S. National Library of Medicine.
[4] PubMed. Literature on prilocaine topical/injection efficacy, onset/duration comparisons, and methemoglobinemia safety studies. National Library of Medicine.